BioStem Technologies Reports First Quarter 2026 Financial Results Amid Strategic Transformation

BioStem Technologies, Inc. (OTC: BSEM) reported financial results for the first quarter ended March 31, 2026, revealing net revenue of $6.1 million, a significant decline from $10.1 million in the fourth quarter of 2025 and $16.0 million in the first quarter of 2025. The company attributed the drop to a strategic transformation following its acquisition of surgical and wound care assets from BioTissue, which shifted focus toward the hospital market. Hospital revenue accounted for 87% of total revenue, or $5.4 million, while physician office revenue contributed $0.8 million.

The acquisition, completed in early 2026, has led to a reassignment of all GPO contracts and an expansion of the direct sales force to 35 representatives, up from 18 at the close of the deal. These changes are part of a broader effort to reposition BioStem as a fully integrated, hospital-focused commercial organization. Chairman and CEO Jason Matuszewski stated that the first quarter marked the beginning of a strategic transformation, with the majority of focus now prioritized on the hospital market to leverage new resources and capture commercially insured patients.

Gross profit for the quarter was $3.8 million, representing a gross margin of 61%, compared to 97% in the fourth quarter of 2025 and 95% in the first quarter of 2025. The sequential decrease in gross margin reflects the mix shift to Neox^® and Clarix^® products, which are subject to a cost-plus markup under the current manufacturing supply agreement. The company expects gross margin to improve significantly upon completion of the planned manufacturing technology transfer in 2027.

Operating expenses totaled $12.6 million, down from $17.3 million in the fourth quarter of 2025 but up from $9.9 million in the first quarter of 2025. The sequential decline was primarily driven by a reduction in bad debt expense, partly offset by the addition of the acquired workforce and expenses related to the BioTissue transaction and the uplist process. GAAP net loss was ($8.8 million), or ($0.52) per share, compared to net income of $3.9 million, or $0.23 per share, in the first quarter of 2025. Adjusted EBITDA was ($5.7 million), compared to $7.8 million in the same period last year.

BioStem also advanced its capital markets strategy by issuing audited financial statements for 2024 and 2025 during the first quarter, progressing toward a planned Nasdaq uplisting. The company expects to provide updates as additional milestones are reached. As of March 31, 2026, cash and cash equivalents totaled $13.7 million, compared to $29.5 million at the end of the fourth quarter of 2025.

For the full year 2026, BioStem expects revenue in the range of $25 million to $29 million. In the second half of the year, with continuing integration of the acquired BioTissue assets, expansion of its salesforce, and execution of its strategic plan, the company expects to drive sequential growth in the hospital business. The physician office market is also expected to stabilize and show sequential revenue growth in the second half of 2026.

The implications of this announcement are significant for stakeholders. The shift to hospital focus and the planned Nasdaq uplisting could enhance BioStem's market visibility and access to capital, but the near-term financial results reflect the costs and challenges of integration. The decline in revenue and gross margin, coupled with a net loss, underscores the transitional nature of this period. However, the company's strategic priorities, including expanding its sales force and achieving manufacturing technology transfer, are designed to position BioStem for durable long-term growth. Investors and industry observers will closely monitor the company's ability to execute on these plans and achieve the projected revenue growth in the latter half of 2026.

For more information, visit BioStem's website and follow the company on PRISM MediaWire for updates.